AzTrials
AzTrials

Type 2 DiabetesPhase 1GIP-PETNCT01880827

Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery

A Phase 1 study testing Roux-en-Y, GIP-infusion and GLP-1 in people with Type 2 Diabetes and Obesity, run by Turku University Hospital at 1 site in Finland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems. Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Type 2 Diabetes, Obesity
What is being tested?
Roux-en-Y, GIP-infusion and GLP-1
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
1 siteFinland
Study dates
Jan 2013to Jan 2016
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • BMI > 35 kg/m2
  • Type 2 diabetes mellitus (fasting glucose more than 7 mmol/l)
  • Age: 18-60 years
  • Previous, carefully planned, conservative treatments for obesity have failed
  • BMI 18-27 kg/m2
  • Age 18-60 years
  • Fasting plasma glucose less than 6.1 mmol/l
  • Normal glucose tolerance test (OGTT)

Who cannot join

  • BMI over 60 kg/m2
  • Weight more than 170 kg
  • Waist circumference > 150 cm
  • Insulin treatment requiring type 2 diabetes mellitus
  • Mental disorder or poor compliance
  • Eating disorder or excessive use of alcohol
Show all 21Show fewer
  • Active ulcus-disease
  • Pregnancy
  • Past dose of radiation
  • Presence of any ferromagnetic objects that would make MR imaging contraindicated
  • Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
  • Blood pressure > 140/90 mmHg
  • Any chronic disease
  • Mental disorder or poor compliance
  • Any chronic medical defect or injury which hinder/interfere everyday life
  • Eating disorder or excessive use of alcohol
  • Pregnancy
  • Past dose of radiation
  • Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
  • Presence of any ferromagnetic objects that would make MR imaging contraindicated
  • Smoking

Trial locations and contacts

1 site in 1 country.

Finland1 site
  • Turku univercity hospital, PET center

    Turku, 20540

Other trials in Finland

About this study

Official title: The Effects of Glucose-dependent Insulinotrophic Peptide (GIP) and Glucagon-like Peptide 1 (GLP-1) on Splanchnic Redistribution of Blood Flow at Postprandial State and After Roux-en-Y Gastric Bypass and Sleeve

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems.

Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis.

The current study is conducted to investigate the vasoactive roles of the GIP. The investigators aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state.

Read the detailed description

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems, including type 2 diabetes mellitus (T2DM). In T2DM, body is unable to response to circulating insulin levels, which ultimately destroys pancreatic β-cells, leading to chronic hyperglycaemia with ensuing consequences

Intestine is able to produce endocrinologically active substances, which affect to body's intermediary metabolism. One of these substances in glucose-dependent insulinotrophic polypeptide (GIP, part of the incretin family), which potentiates the release of insulin postprandially. However, recent evidence suggests, that GIP may have more harmful than beneficial role in the pathogenesis: it has been shown that GIP participates in the development of insulin resistance, the key defect in the process of metabolic dysfunction. GIP may also regulate postprandial redistribution of splanchnic blood flow which might act in the body's nutrition handling [8].

Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2). Most established of these procedures is a Roux-en-Y gastric bypass (RYGB), where duodenum and proximal jejunum is bypassed. Clinical and research evidence shows that shortly (before any significant weight loss) after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin¬, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis.

Positron emission tomography (PET) is a modern imaging technique, which can be used to study perfusion and metabolism of different organs non-invasively. When radiowater measurement is combined with [15O]CO, both tissues specific perfusion and blood volume can be measured, respectively. When coupled with magnetic imaging (ie. PET-MRI), the volumes-of-interests can be accurately drawn to the desired organs.

The current study is conducted to investigate the vasoactive roles of the GIP. We aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state. Moreover, we hypothesize that the elimination of GIP-effect has a central role in the improved intermediary metabolism observed after bariatric surgery procedures, and that part this change is mediated by changes in splanchnic circulation. Furthermore, we investigate the effect of GLP-1 (glucagon-like peptide 1, another member of incretin family) on splanchnic circulation.

In the present study intestinal, hepatic and pancreatic blood flow and volume are measured using [15O]H2O- and [15O]CO radiotracers and PET-MRI imaging in healthy normal weight volunteers (n = 20, BMI ≤ 27 kg/m2) and in morbidly obese T2DM patients (n = 30, BMI ≤ 35 kg/m2) before and after the bariatric surgery operation. The PET imaging will be performed at fasting state but also separately either during 1) mixed meal solution (MMS), 2) GIP-, or 3) GLP-1-infusion. Also abdominal subcutaneous and visceral adipose tissue, intestinal and hepatic tissue samples will be collected.

Being tested
Roux-en-Y, GIP-infusion, GLP-1, MMS, Sleeve gastrectomy
Keywords
GIP, GLP-1, type 2 diabetes, obesity, splanchnic blood flow, incretin hormones
Medical subject headings
Diabetes Mellitus, Type 2, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Roux-en-YProcedure or surgery

    Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.

  • GIP-infusionDrug

    Blood flow and volume during infusion

  • GLP-1Drug

    Blood flow and volume during infusion

  • MMSDrug

    Blood flow and volume after meal solution

  • Sleeve gastrectomyProcedure or surgery

    as in RYGS group

Study groups in NCT01880827
Study groupRoleWhat they receive
Royx-en-Y surgeryActive comparatorMixed meal test (MMS) with flow studies before and 2 months after the operation
Receives: Procedure: Roux-en-Y; Drug: GIP-infusion; Drug: MMS
ControlActive comparatorHealthy volunteer group, GIP, GLP-1 and MMS studies
Receives: Drug: GIP-infusion; Drug: GLP-1; Drug: MMS
Sleeve gastrectomyExperimentalMixed meal test (MMS) with flow studies before and 2 months after the operation
Receives: Drug: GIP-infusion; Drug: MMS; Procedure: Sleeve gastrectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Splanchnic blood flow

    Flow is measured using radiowater H2O and PET

    Measured: 24 months

Secondary outcomes (1)
  1. GIP and GLP-1 blood concetrations

    Blood concentrations are measured from samples

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jun 2013 (estimated)
  2. Study startJan 2013
  3. Primary completionNov 2015
  4. Study completionJan 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01880827
Sponsor's protocol ID
2012-002689-10
Acronym
GIP-PET
Status last verified
Oct 2021
First submitted
25 Feb 2013
Last updated
20 Oct 2021
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Saari T, Koffert J, Honka H, Kauhanen S, U-Din M, Wierup N, Lindqvist A, Groop L, Virtanen KA, Nuutila P. Obesity-associated Blunted Subcutaneous Adipose Tissue Blood Flow After Meal Improves After Bariatric Surgery. J Clin Endocrinol Metab. 2022 Jun 16;107(7):1930-1938. doi: 10.1210/clinem/dgac191.

    PubMed 35363252
  • Honka H, Koffert J, Kauhanen S, Teuho J, Hurme S, Mari A, Lindqvist A, Wierup N, Groop L, Nuutila P. Bariatric Surgery Enhances Splanchnic Vascular Responses in Patients With Type 2 Diabetes. Diabetes. 2017 Apr;66(4):880-885. doi: 10.2337/db16-0762. Epub 2017 Jan 17.

    PubMed 28096259

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Roux-en-Y, GIP-infusion and GLP-1 in people with Type 2 Diabetes and Obesity, run by Turku University Hospital at 1 site in Finland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Splanchnic blood flow (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01880827, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in